Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: A promising male contraceptive approach

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 2, 1996, Pages 757-762

  Bebb, Richard A ^b   Anawalt, Bradley D ^b   Christensen, Richard B ^b   Paulsen, C Alvin ^b   Bremner, William J ^b   Matsumoto, Alvin M ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVONORGESTREL; MALE CONTRACEPTIVE AGENT; TESTOSTERONE;

ADULT; ARTICLE; AZOOSPERMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HORMONAL THERAPY; HUMAN; MALE; OLIGOSPERMIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SPERMATOGENESIS;

AMERICAS; ANDROGENS; BIOLOGY; COMPARATIVE STUDIES; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE--ADMINISTRACTION AND DOSAGE; CONTRACEPTIVE AGENTS, MALE--ADMINISTRACTION AND DOSAGE; CONTRACEPTIVE AGENTS, MALE--SIDE EFFECTS; CONTRACEPTIVE AGENTS, PROGESTIN--ADMINISTRACTION AND DOSAGE; CONTRACEPTIVE AGENTS--ADMINISTRACTION AND DOSAGE; CONTRACEPTIVE AGENTS--SIDE EFFECTS; DEVELOPED COUNTRIES; ENDOCRINE SYSTEM; FAMILY PLANNING; HORMONES; LEVONORGESTREL--ADMINISTRACTION AND DOSAGE; NORTH AMERICA; NORTHERN AMERICA; PHYSIOLOGY; RESEARCH METHODOLOGY; RESEARCH REPORT; SPERMATOGENESIS BLOCKING AGENTS; STUDIES; TESTOSTERONE--ADMINISTRACTION AND DOSAGE; UNITED STATES; WASHINGTON;

ADULT; CHOLESTEROL, HDL; CONTRACEPTIVE AGENTS, MALE; FOLLICLE STIMULATING HORMONE; HUMANS; LEVONORGESTREL; LUTEINIZING HORMONE; MALE; PLACEBOS; SPERM COUNT; SPERMATOGENESIS; TESTOSTERONE; WEIGHT GAIN;

EID: 0030050344     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.2.757     Document Type: Article

References (41)

1. Youssef H. 1993 The history of the condom. Proc R Soc Med 86:226-228.
2. Cummings DE, Bremner WJ. 1994 Prospects for new hormonal male contraceptives. Endocrinol Metab Clin North Am. 23:893-922.
3. World Health Organization Task Force on Psychosocial Research in Family Planning, Special Programme of Research, Development, and Research Training in Human Reproduction. 1982 Hormonal contraception for men: acceptability and effects on sexuality. Stud Fam Plan. 13:328-342.
4. Keith L, Keith D, Bussell R, Wells J. 1975 Attitudes of men toward contraception. Arch Gynakol. 220:89-97.
5. Matsumoto AM, Bremner WJ. 1987 Endocrinology of the hypothalamic-pituitary axis with particular reference to the hormonal control of spermatogenesis. Bailliere Clin Endocrinol Metab. 1:71-87.
6. Matsumoto AM, Karpas AE, Paulsen CA, Bremner WJ. 1983 Reinitiation of sperm production in gonadotropin-suppressed normal men by administration of follicle-stimulating hormone. J Clin Invest. 72:1005-15.
7. Matsumoto AM, Paulsen CA, Bremner WJ. 1984 Stimulation of sperm production by human luteinizing hormone in gonadotropin-suppressed normal men. J Clin Endocrinol Metab. 59:882-887.
8. World Health Organization Task Force on Methods for the Regulation of Male Fertility. 1990 Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet. 336:955-959.
9. Paulsen CA, Bremner WJ, Leonard JM. 1982 Male contraception: clinical trials. In: Mishell DR, ed. Advances in fertility research. New York: Raven Press; 157-170.
10. Bagatell CJ, Matsumoto AM, Christensen RB, Rivier JE, Bremner WJ. 1993 Comparison of a gonadotropin releasing hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. J Clin Endocrinol Metab. 77:427-432.
11. Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE, Bremner WJ. 1994 Metabolic and behavioral effects of high-dise, exogenoustestosterone in healthy men. J Clin Endocrinol Metab. 79:561-567.
12. Wallace EM, Pye SD, Wild SR, Wu FCW. 1993 Prostate-specific antigen, and prostate size in men receiving exogenous testosterone for male contraception. Int J Androl. 16:35-40.
13. Fogh M, Corker CS, McLean H, et al. 1980 Clinical trial with levo-norgestrel and testosterone oenanthate for male fertility control. Acta Endocrinol (Copenh). 95:251-257.
14. Føgh M, Nicol K, Petersen IB, Schou G. 1980 Clinical evaluation of long-term treatment with levo-norgestrel and testosterone enanthate in normal men. Contraception. 21:631-639.
15. Matsumoto AM. 1990 Effects of chronic testosterone administration in normal men: safety and efficacy of high dose testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production. J Clin Endocrinol Metab. 70:282-287.
16. Bagatell CJ, Knopp RH, Vale WW, Rivier JE, Bremner WJ. 1992 Physiologic testosterone levels in normal men suppress high-density lipoprotein cholesterol levels. Ann Intern Med. 116:967-973.
17. Spona J, Schneider WHF, Bieglmayer CH, Schroeder R, Pirker R. 1979 Ovulation inhibition with different doses of levonorgestrel and other progestogens: clinical and experimental investigations. Acta Obstet Gynecol Scand. 88(Suppl):7-15.
18. Sivin I. 1988 International experience with Norplant and Norplant-2 contraceptives. Stud Fam Plan. 19:81-94.
19. Ahsan R, Sufi SB, Cekan S. 1988 Laboratory method manual for the radioimmunoassay of levonorgestrel, norethisterone and medroxyprogesterone acetate. London: WHO CCR for Immunoassay.
20. Behre HM, Baus S, Klesch S, Keck C, Simoni M, Nieschlag E. 1995 Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders. J Clin Endocrinol Metab. 80:2394-2403.
21. Matsumoto AM, Paulsen CA, Hopper BR, Rebar RW, Bremner WJ. 1983 Human chorionic gonadotropin and testicular function: stimulation of testosterone, testosterone precursors, and sperm production despite high estradiol levels. J Clin Endocrinol Metab. 56:720-728.
22. 2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem. 28:1379-1388.
23. Warnick GR. 1986 Enzymatic methods for the quantification of lipoprotein lipids. In: Albers JJ, Segrest JP, eds. Methods in enzymology. Orlando: Academic Press; vol 129:101-123.
24. Friedwald WT, Levy RI, Fredrickson DS. 1972 Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative centrifuge. Clin Chem. 18:499-501.
25. Bremner WJ, Matsumoto AM, Sussman AM, Paulsen CA. 1981 Follicle-stimulating hormone and human spermatogenesis. J Clin Invest. 68:1044-1052.
26. Gordon DL, Moore DL, Thorslund T, Paulsen CA. 1965 The determination of size and concentration of human sperm with an electronic particle counter. J Lab Clin Med. 65:506-512.
27. WHO. 1992 WHO laboratory manual for the examination of human semen and sperm-cervical mucus interaction, 3rd ed. Cambridge: Cambridge University Press; 7-8.
28. Service RF. 1994 Reproductive biology. Contraceptive methods go back to basics. Science. 266:1480-1481.
29. Wu FCW, Aitken RJ. 1989 Suppression of sperm function by depot medroxyprogesterone acetate and testosterone enanthate in steroid male contraception. Fertil Steril. 51:691-698.
30. Alvarez-Sanchez F, Brache V, Leon P, Faundes A. 1979 Inhibition of spermatogenesis with monthly injections of medroxyprogesterone acetate and low dose testosterone enanthate. Int J Androl. 2:136-149.
31. Faundes A, Brache V, Leon P, Schmidt F, Alvarez-Sanchez F. 1981 Sperm suppression with monthly injections of medroxyprogesterone acetate combined with testosterone enanthate at high dose (500 mg). Int J Androl. 4:235-245.
32. Schearer SB, Alvarez-Sanchez F, Anselmo J, et al. 1978 Hormonal contraception for men. Int J Androl. 2(Suppl):680-712.
33. Meyer JM, Walker PA, Emory LE, Smith ER. 1985 Physical, metabolic, and hormonal effects on men of long-term therapy with medroxyprogesterone acetate. Fertil Steril. 43:102-109.
34. Meriggiola MC, Valdiserri A, Pavani A, et al. A combined regimen of cyproterone acetate (CPA) and testosterone enanthate (TE) as a potentially highly effective male contraceptive: effects on spermatogenesis and hormones [Abstract]. Proc of the 77th Annual Meet of The Endocrine Soc. 1995; 85.
35. Mauvais-Jarvis P, Kuttenn F, Baudot N. 1974 Inhibition of testosterone conversion to dihydrotestosterone in men treated percutaneously by progesterone. J Clin Endocrinol Metab. 38:142-147.
36. Wu FCW, Anderson RA. Comparison between testosterone-induced azoospermia and oligospermia in a male contraceptive study: pharmacokinetics, pharmaoodynamics of testosterone enanthate administration and 5-alpha reductase activity [Abstract]. Proc of the 75th Annual Meet of The Endocrine Soc. 1993; 53.
37. Wallace EM, Wu FCW. 1990 Effect of depomedroxyprogesterone acetate and testosterone oenanthate on serum lipoproteins in man. Contraception. 41:63-71.
38. Jacobs DR, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA. 1990 High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the lipid research clinics prevalence study. Am J Epidemiol. 131:32-47.
39. Goldbourt U, Holtzman E, Neufield HN. 1985 Total and high density lipoprotein cholesterol in the serum and the risk of mortality: evidence of a threshold effect. Br Med J. 290:1239-1243.
40. Castelli WP, Garrison RJ, Wilson PWF, Abbott GD, Kalsousdian S, Kannel WB. 1986 Incidence of coronary heart disease and lipoprotein cholesterol levels. JAMA. 256:2835-2838.
41. Speroff L, DeCherney A. 1993 Evaluation of a new generation of oral contraceptives. The advisory board for the new progestins. Obstet Gynecol. 81: 1034-1047.